Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김동선 | - |
dc.date.accessioned | 2020-04-08T05:56:54Z | - |
dc.date.available | 2020-04-08T05:56:54Z | - |
dc.date.issued | 2019-03 | - |
dc.identifier.citation | Endocrinology and Metabolism, v. 34, NO 1, Page. 53-62 | en_US |
dc.identifier.issn | 2093-596X | - |
dc.identifier.issn | 2093-5978 | - |
dc.identifier.uri | https://e-enm.org/DOIx.php?id=10.3803/EnM.2019.34.1.53 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/148384 | - |
dc.description.abstract | The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including ex-tended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Korean Endocrine Society | en_US |
dc.subject | Acromegaly | en_US |
dc.subject | Somatostatin analogues | en_US |
dc.subject | Octreotide | en_US |
dc.subject | Lanreotide | en_US |
dc.subject | Pasireotide | en_US |
dc.title | Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement | en_US |
dc.type | Article | en_US |
dc.relation.volume | 34 | - |
dc.identifier.doi | 10.3803/EnM.2019.34.1.53 | - |
dc.relation.page | 53-62 | - |
dc.relation.journal | Endocrinology and Metabolism | - |
dc.contributor.googleauthor | Chin, Sang Ouk | - |
dc.contributor.googleauthor | Ku, Cheol Ryong | - |
dc.contributor.googleauthor | Kim, Byung Joon | - |
dc.contributor.googleauthor | Kim, Sung-Woon | - |
dc.contributor.googleauthor | Park, Kyeong Hye | - |
dc.contributor.googleauthor | Song, Kee Ho | - |
dc.contributor.googleauthor | Oh, Scungjoon | - |
dc.contributor.googleauthor | Yoon, Hyun Koo | - |
dc.contributor.googleauthor | Lee, Eun Jig | - |
dc.contributor.googleauthor | Kim, Dong Sun | - |
dc.relation.code | 2019045231 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | dongsun | - |
dc.identifier.orcid | https://orcid.org/0000-0003-1256-7648 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.